Review Article

A Role for Folate in Microbiome-Linked Control of Autoimmunity

Christine Mölzer, Heather M. Wilson, Lucia Kuffova, and John V. Forrester

1University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, UK
2Eye Clinic, Aberdeen Royal Infirmary, Aberdeen, UK

Correspondence should be addressed to Christine Mölzer; christine.moelzer@abdn.ac.uk

Received 16 March 2021; Accepted 4 May 2021; Published 20 May 2021

Copyright © 2021 Christine Mölzer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The microbiome exerts considerable control over immune homeostasis and influences susceptibility to autoimmune and autoinflammatory disease (AD/AID) such as inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes (T1D), psoriasis, and uveitis. In part, this is due to direct effects of the microbiome on gastrointestinal (GI) physiology and nutrient transport, but also to indirect effects on immunoregulatory controls, including induction and stabilization of T regulatory cells (T_{reg}). Secreted bacterial metabolites such as short-chain fatty acids (SCFA) are under intense investigation as mediators of these effects. In contrast, folate (vitamin B9), an essential micronutrient, has attracted less attention, possibly because it exerts global physiological effects which are difficult to differentiate from specific effects on the immune system. Here, we review the role of folate in AD/AID with some emphasis on sight-threatening autoimmune uveitis. Since folate is required for the generation and maintenance of T_{reg}, we propose that one mechanism for microbiome-based control of AD/AID is via folate-dependent induction of GI tract T_{reg}, particularly colonic T_{reg} via anergic T cells (T_{an}). Hence, folate supplementation has potential prophylactic and/or therapeutic benefit in AID/AD.

1. Introduction

Autoimmune diseases (AD) develop when there is breakdown of immunological tolerance to self-antigen in the adaptive immune system while autoinflammatory diseases (AID) occur when there are defects or dysregulation in the innate immune system [1]. In both cases, a disordered microbiome has been implicated and, by inference, an altered bacterial flora including its secreted products [2]. Classical AD such as multiple sclerosis (MS) [3], type 1 diabetes (T1D) [4], and rheumatoid arthritis (RA) [5] is kept at bay by a healthy microbiome, while probable AID such as inflammatory bowel disease (IBD), Behçet’s uveitis, and ankylosing spondylitis (AS) are negatively affected by a disordered microbiome (reviewed in [6]). Psoriasis, a debilitating skin inflammation, and uveitis, a major sight-threatening disease in which infection may be a direct or indirect cause, are considered in many cases to be either an AD or an AID [7, 8].

In both AD and AID, there is failure of immune regulation (tolerance) and a disturbed microbiome. Identifying possible causal links between these two biological domains is a major focus. In adaptive immunity, tolerance (homeostasis) is maintained by autoreactive T cell deletion/anergy or suppression by T regulatory cells (T_{reg}). T_{reg} are also effective in controlling innate immunity by regulating the activity of myeloid and NK cells [9] and so contribute to preventing AID. Circumstantial evidence for their role in AD and AID is the decline in T_{reg} numbers in many of these conditions such as AS [10] as well as the effectiveness of adoptive T_{reg} therapy in experimental models of AD and AID.

2. The Colonic Microbiota Shapes the Host’s Health

The prenatal GI tract is sterile due to the protective immunological placental barrier preventing bacterial translocation into the fetal organism. Microbial colonization develops gradually when environmental contact first occurs upon delivery. This has significant implications for overall health
in later life [11, 12]. For instance, the expanding gut microbiome exerts its effects on brain- (CNS-) related immune privilege (IP) in that the blood-CNS barriers only reach maturity in the neonatal period [13–15]. A key colonic metabolite that can modulate the immune system is folate. Naturally, occurring folate/vitamin B9 (pteroyl-glutamic acids and oligo-glutamic acid conjugates) and its synthetic form folic acid (FA) are water-soluble B vitamins that must be ingested through the diet (e.g., legumes and leafy greens [16, 17]) or supplements [18]. Commensal bacteria [19] are also capable of synthesizing folate and other B vitamins. Glutamic compounds [20] occur in the body as different metabolites with variable bioavailability [21] and the terms folate and FA are often used interchangeably. The role of folate in hematopoiesis, reproductive health and foetal development are well known, and an extended role for the vitamin particularly in later life is recognized in preventing a decline in cognitive and neurological functioning [16, 22, 23]. Indeed, most likely due to inadequate intake, folate deficiency is more prevalent in the older population [24] contemporaneously with a higher incidence of chronic disease.

Hence, a balanced microbiome with adequate folate and micronutrient production maintains homeostasis. Recently, however, the microbiome has come under scrutiny as a source of pathogenic antigens capable of inducing or promoting AD [25–28]. This is particularly linked to dysbiosis [29] and may be the result of infection with pathogenic bacteria, loss of commensal bacteria, or reduction in microbial diversity [30]. The human intestinal epithelium covers as much as 400 m² of surface area [31] with more than ten times as many resident microbes as the total number of cells in the body [32]. Overall, the gut microbiota comprises five phyla and about 160 species in the large intestine [33], and the number of genes of the intestinal microbiota is 150 times greater than the human genome [34]. Qualitative and quantitative changes in the microbial flora, their metabolic activity, and their local distribution [35] are a typical feature of IBD [36] that is otherwise characterized by the infiltration of the lamina propria with a mixed leukocyte population expressing proinflammatory cytokines [37]. Whether dysbiosis represents the cause or result of IBD (reviewed in [38]), it is a correlated biomarker of extraintestinal inflammatory disease (reviewed in [25, 39]). While mechanistic evidence is still limited, dysbiosis has long been linked to AD [40], including noninfectious uveitis [41–43], (reviewed in [25]), often occurring simultaneously with acute flare-ups of colitis [44]. Thus, it can be seen that dysbiosis and similar microbiota-related environmental factors impact up to 70% of all AD [45, 46], and while the etiology of IBD itself is not fully understood, it is considered to be the result of an interplay between environment/nutrition, microbiota, gastrointestinal immunity, and epigenetics.

3. The Microbiome Promotes Immunological Tolerance via an Immune Privilege-Like Mechanism

Immune privilege is a relative property of all tissues reflecting various degrees of tissue-based immunological tolerance [47] and has particular relevance for the large intestine, now considered a secondary immune organ [48, 49]. “Unconventional” IP of the gut [50] tolerates trillions of commensals and has two components, a physicochemical barrier and an immunological barrier [51]. The physical barrier is provided by the two cellular barriers which prevent translocation of pathobionts from the intestine to the general circulation (reviewed in [47]). These include a monolayer of enteroctye epithelium (i.e., an intestinal epithelial barrier, IEB) covering the entire mucosa and the subjacent lamina propria and a stringent gut-vascular barrier (GVB). The physical barrier to the passage of small molecules is provided by immunologically responsive [50] intraepithelial tight junctions [52] while a chemical barrier derives from specialized enteroctyes (mucus-producing goblet cells and Paneth cells) which secrete antimicrobial peptides (reviewed in [53, 54]). A further physical barrier to hematogenous passage of any pathogens which may have penetrated the epithelium is provided by the GVB [55] with its closely associated pericytes and enteric glial cells which serve a vital function in retaining barrier properties [56–60].

The immunological component of the gut barrier is provided by a wealth of immune cells in the gut, including tol- erogenic DC, several types of classical T cells including Treg, three sets of innate lymphoid cells (ILC), myeloid suppressor cells, and mucosa-associated invariant T (MAIT) cells. These cells regulate aspects of both the adaptive and innate immune systems and are under the control of secreted factors both by host cells and the microbiome. For instance, flagellin associated mostly with gram-negative bacteria (e.g., E.coli and Salmonella) binds TLR5 on CD103+ mucosal DC which secrete IL23 to act on ILC which in turn release IL22 to then induce the gut epithelium to release antimicrobial peptides [30], and colonic Clostridia through their metabolic activity have been found to induce and impact the colonic distribution of Treg in mice [61–63]. Treg are known to be stabilized by folate [64–66], that in turn is synthesized by some commensals including Clostridia, Lactobacilli, and Bifidobacteria [67]. These findings point to a tolerizing immunological role for the commensal microbiome that has the potential to exert effects on disease induction and progression. How gut-derived leukocytes might cross distant barriers at target sites and induce AD/AID remains to be clarified. Several mechanisms have been proposed [25] viewed from both the perspective of an adaptive immune response (TCR activation) and dysregulation of the microbiome.

4. The Microbiome Mediates Immunological Tolerance via the Products of Microbial Fermentation

Microbial fermentation in the gut generates secreted products which directly modify immune activity (Figure 1). These include products of tryptophan metabolism, short-chain fatty acids (SCFA), and folate.

4.1. Tryptophan. Tryptophan is an essential amino acid (AA) that is delivered through the diet, particularly dairy products
and fish. Host metabolic pathways of tryptophan include the serotonin and kynurenic routes, the latter of which via indoleamine 2,3 dioxygenase (IDO) is a major tolerizing pathway in DC and macrophages. Its downstream products such as kynurenine acid (KA), 3-hydroxy-anthranilic acid (HAA), quinolinic acid (QA), and niacin (vitamin B3) suppress both innate and adaptive immunity and promote immunological tolerance and gut homeostasis (reviewed by [68]). Tryptophan can also be metabolized by microbiota-generating metabolites that interact with the aryl hydrocarbon receptor [69]. The IDO pathway and the AhR system are active in many cell types and important in homeostasis, e.g., in epithelial health. In immune cells, it mediates tolerance and suppresses inflammation via DC-mediated induction of $T_{\text{reg}}$.

4.2. Retinoic Acid. Induction of $T_{\text{reg}}$ in the gut may also require supplementation of dietary vitamin A (retinol) which is directly converted to bioavailable all trans-retinoic acid (atRA) by gut-associated lymphoid tissue DC [70] and in both mice and humans promotes conversion of naïve T cells into tissue-specific (mucosa homing) FoxP3$^+$ $T_{\text{reg}}$ through FoxP3 promoter histone acetylation [71]. Moreover, atRA prevents the IL6-induced conversion of $T_{\text{reg}}$ into Th17 cells and boosts the generation of TGFβ-induced $T_{\text{reg}}$ in vitro that were effective in suppressing inflammation in a colitis model [72]. Similarly, atRA stabilized $T_{\text{reg}}$ in an experimental autoimmune encephalitis model (EAE) through a TGFβ-dependent pathway [73], and in an experimental autoimmune uveitis (EAU) model, atRA acted as an adjuvant to induce antigen-specific type 1 $T_{\text{reg}}$ (Tr1) attenuating autoimmunity [74].

4.3. SCFA. SCFA produced by the microbiome are major effectors of immunomodulation. Three main SCFA are recognized: acetate, butyrate, and propionate. Acetate accounts for ~50-70%, propionate ~20%, and butyrate, which is selectively restricted to certain Clostridia species, makes up the remainder [75]. SCFA regulates intestinal $T_{\text{reg}}$ and macrophages, and the majority of SCFA produced remain in the gut generating beneficial effects locally, while only negligible quantities escape into the general circulation [76]. Dysbiosis in IBD (colitis) patients is typically associated with a reduced number of bacteria that produce SCFA particularly butyrate and propionate (Figure 1(b)). These include Firmicutes such as cluster IV Clostridia next to Bifidobacteria. Propionate and butyrate suppress inflammation by promoting the generation of tolDC and $T_{\text{reg}}$ (reviewed in [77]). In germ-free mice treated with antibiotics, stool butyrate concentrations were decreased relative to littermate mice [78]. Oral acetate supplementation in NOD mice reduced autoactive T cells in lymphoid tissues in a B cell-mediated fashion. A butyrate-rich diet increased $T_{\text{reg}}$ while a combination of both SCFA improved gut barrier function and decreased diabetogenic IL21 in serum of NOD mice [79]. Colonic concentrations of SCFA, including butyrate, correlated with the number of FoxP3$^+$ $T_{\text{reg}}$ in the caecum of mice [62]. Furthermore, oral administration of butyrate to mice increased the FoxP3 expression in $T_{\text{reg}}$, higher numbers of $T_{\text{reg}}$ in mucosal tissues, and an enhanced ability of DC to induce $T_{\text{reg}}$ differentiation.
These data suggest that butyrate (and to a lesser extent propionate) promotes extrathymic differentiation of T<sub>reg</sub> [78]. Recent findings from human trials investigating AD (MS and neuromyelitis optica) support this hypothesis [80, 81].

Vitamin B3 (niacin) also exerts immune-modulatory functions by increasing T<sub>reg</sub> cell numbers and functioning [82, 83] together with butyrate through activation of its receptor Gpr109a, thereby protecting against colon inflammation [83].

Mechanistically, SCFA act by inhibiting histone deacetylases (HDAC) [78], in antigen-presenting cells affecting atRA and IL10 production [93]. HDAC also induce apoptosis in T<sub>eff</sub> cells [94] and engage in loosening of chromatin, thus enabling transcription factor accessibility to the DNA backbone. These findings suggest a balancing effect of SCFA on mucosal and systemic immunity, possibly affecting inflammation in secondary organs, since mucosal inflammation is typically associated with epithelial damage ("leaky gut"). Fukuda et al. [95] demonstrated that acetate (produced by Bifidobacteria and Clostridia) may improve leaky gut by restoring gut epithelial integrity through activation of the inflammasome and IL18 [96].

4.4. Folate. Folate is synthesized de novo from phosphoehnolpyruvate and guanosine triphosphate (GTP) and secreted by commensals of the phylum Bacteroides (Prevotella, Bacteroides, Porphyromonas [97]) (reviewed in [98]) (Figure 2). In contrast to dietary vitamins that are mostly absorbed in the small intestine, microbial folate metabolites are mainly absorbed in the colon where they are produced [99, 100] and assimilated into host tissues [100–102]. Various glutamylation profiles for commensal gut microbes (i.e., species-specific patterns of folate derivatives) may affect folate bioavailability in the intestine [84] and the general circulation [67], and the colon is recognized as a significant folate depot [19]. Folic acid deficiency is associated with disruptions of intestinal integrity and persistent diarrhea (reviewed in [103]). A folate-producing microbiome likely influences the T cell methylene, but the mechanism is unclear [94]. Rats fed a probiotic formulation of folate-producing Bifidobacteria exhibited increased plasma folate levels, confirming in vivo production and absorption of the vitamin. The same supplement when administered to humans raised folate concentration in feces (reviewed in [67]). A sufficient folate status therefore is likely to reduce the risk of AD/AID including uveitis.

5. Microbiome-Mediated Immune Tolerance Is Maintained through Regulatory and Anergic T Cells under the Influence of Folate

Deletion, anergy, and induction of T<sub>reg</sub> are the tenets of immune tolerance. T<sub>reg</sub> are generated centrally in the thymus de novo (natural T<sub>reg</sub> or nT<sub>reg</sub>) and in the periphery (pT<sub>reg</sub>) from conventional T cells (T<sub>conv</sub>). Most autoreactive T<sub>conv</sub> are deleted in the thymus or periphery but a proportion may enter a state of anergy (T<sub>an</sub>) as they become tolerized [104–107]. pT<sub>reg</sub> in the gut are recognized as major contrib-

![Figure 2: Bacterial route of de novo folic acid synthesis. Certain commensals of the human colonic flora produce folate de novo through the chorismate pathway (from phosphoehnolpyruvate + guanosine triphosphate, GTP). Further, 77% of the bacterial genome is capable of synthesizing folate using freely available p-aminobenzoic acid (pABA) and dihydropterotate diphosphate (pteridine)2 [84]. The pathway engages a series of enzymatic reactions (red protein symbols) including dihydropterotate synthetase and dihydrofolate synthetase. The resulting dihydrofolate (via the dihydropterotate intermediate) must be enzymatically reduced (through dihydrofolate reductase) to generate biologically active tetrahydrofolate. This process can be blocked by the folate antagonist methotrexate (Mtx), used for controlling some forms of autoimmune disease including anterior uveitis. Folate metabolites synthesized by commensals are used by the bacteria themselves (e.g., for DNA-synthesis or anabolic pathways such as generation of amino acids, AA). The remaining unused folates are released into the gut lumen and absorbed in a receptor-mediated fashion absorption into the circulation.](image-url)
generate a pool of $T_{an}$ from $T_{conv}$, which have the option of losing their methylation sites and becoming stable $T_{reg}$. This degree of flexibility underpins the properties of immunological tolerance.

The mechanism whereby folate modifies $T_{reg}$ appears to be through inhibiting cell death specifically by induction of Bcl-2. Adoptive transfer of $T_{reg}$-depleted cell suspensions induced autoimmune gastritis in susceptible nude mice [65] while adoptive transfer of folate-supplemented $T_{reg}$ prolonged the cells’ survival and protected the mice from the disease. Mice treated with the folate antagonist methotrexate (Mtx) show impaired survival of $T_{reg}$ and decreased expression of Bcl-2, while in vivo depletion of dietary folate resulted in a reduction in $T_{reg}$ cell numbers in the small intestine. In this study, folate was required for the survival of differentiated n$T_{reg}$ but not for the conversion of naive T cells into p$T_{reg}$ [66]. Remarkably, this effect is different from that of atRA, and less so vitamin D3, which both enhance the differentiation of naive T cells into p$T_{reg}$ [72, 116–119], emphasizing a unique role for folate in the generation of n$T_{reg}$ [113]. This selective effect of folate on maintenance of FoxP3$^{+}$ $T_{reg}$ has been further demonstrated [64], while a diet deficient in folate resulted in a marked reduction of FoxP3$^{+}$ $T_{reg}$ but not other T cell populations, in the colon. In the same study, blockade of FR4 and treatment with Mtx, led to decreased colonic FoxP3$^{+}$ $T_{reg}$ and increased autoimmune bowel inflammation. These data have implications for human biology but remain to be verified in man, particularly as n$T_{reg}$ exhibit some degree of phenotypical variation between mice and humans [120, 121].

6. FoxP3 in T Regulatory Cells Controls the Expression of the Folate Receptor

At a molecular level, folate stabilizes overall cell proliferation, controls DNA modification (histone methylation), and metabolically detoxifies the prooxidative AA intermediate homocysteine, by recycling it to the essential sulphur-rich AA methionine (Figure 3) or alternatively, the semiessential AA cysteine (not depicted in Figure 3).

Folate is delivered to cells through three known routes: (1) via folate receptors (FR)/folate-binding protein (Folbps) [122], (2) the reduced folate carrier, and (3) through the proton-coupled folate transporter [123]. In humans, there are four FR isoforms, namely, α, β, γ, and δ, with tissue-specific expression patterns [122, 124]. Initially, three FR isoforms with greater than 70% homology were identified in humans (i.e., α, β, and γ) and two in mice (i.e., α and β) [125]. The human receptor homologue for murine FR6 (also known as FR4 or folate binding protein 3) is expressed on splenic and thymic lymphocytes [126] and is particularly abundant on both n$T_{reg}$ and p$T_{reg}$ in both mice and humans [65, 127, 128]. Since FR4 is a glycosyl phosphatidylinositol–anchored protein, adapter molecules may assist the receptor in the maintenance of n$T_{reg}$ cell survival [129, 130] but little is known about its precise role. Importantly, based on its $T_{reg}$-specific expression, FR4 can be used to discriminate $T_{reg}$ from $T_{conv}$ following antigen stimulation [65].

The high folate requirement of murine n$T_{reg}$ is met via upregulation of the FR4 surface expression, under the control of FoxP3 [65], suggesting a tight crosstalk between the transcription factor and receptor expression. Folate may also influence other $T_{reg}$ molecular pathways (summarised in [114]).

7. The Microbiome in Uveitis

Uveitis (intraocular inflammation) is an AD/AID which causes significant blindness and visual handicap worldwide (10–15% in the developed world) [131]. A failure of $T_{reg}$ as an underlying pathogenesis is suggested by the reduced numbers of circulating $T_{reg}$ in patients with uveitis, and since the number of circulating $T_{reg}$ correlates with certain taxa in the colonic microbiome and become stabilized in vivo by bacterial metabolites ([61, 63] see above), this supports a role for a dysregulated microbiome in uveitis. Uveitis occurs in two broad forms, anterior uveitis involving the iris and ciliary body and is closely linked to ankylosing spondylitis (AS) in many cases, and posterior uveitis involving the retina which is protected by the blood retinal barrier (BRB). Both forms of uveitis are subject to changes in the microbiome,
particularly anterior uveitis, in conjunction with AS and IBD [132]. Specific autoantigens for human uveitis have been intensively sought but not identified (reviewed in [7]).

Recently, an experimental model of spontaneous uveitis (experimental autoimmune uveoretinitis, EAU) in a transgenic TCR mouse with specificity for a retinal protein (potential autoantigen: interphotoreceptor retinol binding protein, IRBP), in which the mice next to uveitis also develop dysbiosis, has been described. It was suggested that the pathogenic antigen was an unidentified commensal protein which was crossreactive with the IRBP-TCR and, due to the loss of colonic IP (leaky gut), bacterial forms translocated across the gut wall and activated T cells in the gut draining lymph node. Included in this T cell population were autoreactive IRBP-specific T cells which in this mouse model are in increased frequency (~20%) [133]. Once activated, circulating T cells crossed the BRB and were further activated on contact with cognate antigen in the retina causing uveitis and retinal damage. The definitive proof-of-principle experiment was that no uveitis occurred in germ free IRBP-TCR mice, i.e., animals lacking a microbiome. Whether the commensal antigen translocated freely in lymphatics or was carried as cargo by trafficking antigen presenting cells is not clear, but trafficking of leukocytes to and from the gut occurs in both health and disease [85, 86], emphasizing a tight immunological crosstalk between the intestine and extraintestinal tissues. While an interesting hypothesis, a gut occurs in both health and disease [85, 86], emphasizing increased frequency (~20%) [133]. Once activated, circulating T cells crossed the BRB and were further activated on contact with cognate antigen in the retina causing uveitis and retinal damage. The definitive proof-of-principle experiment was that no uveitis occurred in germ free IRBP-TCR specific mice, i.e., animals lacking a microbiome. Whether the commensal antigen translocated freely in lymphatics or was carried as cargo by trafficking antigen presenting cells is not clear, but trafficking of leukocytes to and from the gut occurs in both health and disease [85, 86], emphasizing a tight immunological crosstalk between the intestine and extraintestinal tissues. While an interesting hypothesis, a gut occurs in both health and disease [85, 86], emphasizing a tight immunological crosstalk between the intestine and extraintestinal tissues.

In a separate study, upregulation of miRNA-223 was detected in IRBP-specific Th17 cells from an induced EAU mouse model [139] as well as in uveitis patients’ sera [140]. The latter study revealed a pattern of six miRNAs that were linked to inflammatory signalling cascades, such as MAPK, FOXO, and VEGF. Of those miRNAs highlighted, miRNA-223 stood out, as it not only promoted an inflammatory response through activation of DC and T cells but also hinted at a dysbiotic microbiome [141–143] with reduced colonic folate synthesis/bioavailability. Interestingly, hyperhomocysteinemia, and its underlying polymorphisms in folate metabolism-associated genes [144], occurs in autoinflammatory (Behçet’s) uveitis patients [145] indicating a link for FA in noninfectious uveitis [146]. It is clear thus that in the model of autoimmune uveitis, both experimental and clinical there is a strong association with dysbiosis and dysregulated folate metabolism. There is also a clear deficiency in the \( T_{reg} \) function and/or numbers. Since folate is required for \( T_{reg} \) physiology [65] the link between folate, \( T_{reg} \) and autoimmune uveitis speaks for itself [64, 66, 77]. We propose that folate deficiency as part of a dysfunctional microbiome is part of the backdrop to autoimmune uveitis and probably other AD/AID.

8. The Microbiome and Its Metabolites as Therapeutic Intervention

There is much interest in potential therapeutic modulation of AD using microbiome-based metabolites including fecal microbial transplantation (FMT), SCFA, folate, and probiotics.

8.1. FMT. FMT has been proposed for treatment of AD but it is as yet unclear whether this approach may have a beneficial or deleterious effect [147]. FMT from patients with autoimmune Vogt-Kayanagi-Harada disease (VKH) exacerbated EAU in mice [148]. To date, there are no studies of FMT in uveitis patients.

8.2. SCFA. SCFA have been shown to be reduced in patients with RA and in mice with experimental arthritis and interestingly, treatment of such mice with SCFA induced upregulation of the AhR in regulatory B cells [149]. SCFA such as butyrate and propionate have also been effective in reducing inflammation in experimental models including in EAU [86] and endotoxin-induced uveitis [150] but to date have not been translated to clinical use in uveitis. However, the SCFA propionate has been trialed in patients with MS, and a significant shift in the balance towards \( T_{an} \) to \( T_{reg} \) conversion [90].

It is therefore relatively unexplained how the microbiome influences susceptibility to uveitis and in the context of this review, what might be the role of folate? Recent studies (reviewed in [136]) proposed that EAU in mice might be mediated through epigenetic changes possibly involving Tbx21 and Rorc—two transcription factors important for the differentiation of \( T_{reg} \) and Th17 cells [137]. Interestingly, hypomethylation of these factors (along with FoxP3) was found in the retinas and RPE-choroidal tissues of B10.RIII mice developing CFA-induced EAU after IRBP immunization, together with an increase in proinflammatory IFNγ and IL17 and reduced DNA-methyltransferase 1 (DNMT1) expression in these tissues corresponding to the genes’ methylation status ([138]; reviewed in [136]). These findings highlight a requirement for folate to modulate inflammation at an epigenetic level in the prevention of AD and although not stated in that paper, may be linked to the interconversion of \( T_{an} \) to generate stable \( T_{reg} \) all under the control of FoxP3.

Folate and folate supplementation have also been proposed for therapy of AD. In a focal model of EAE, a novel folate-aminopterin construct (EC2319) was found to be tolerated and provided anti-inflammatory benefit by suppressing CD68+ macrophage activity [152]. Similarly, a novel FR-targeted drug EC0746 was found to be effective in the treatment of EAE and EAU [153]. The folate receptor FRβ is expressed on activated macrophages and has been
suggested as a target in AD including RA [154]. However, we suggest here that the preferential expression of FR4 on T_{reg} promotes their expansion, particularly of colonic T_{reg} which then have the ability to suppress macrophage activity.

8.4. Probiotics. Delivery of dietary folate to supplement microbiome-generated folate is also a promising approach and may be incorporated in probiotics [155] in combination with prebiotics [156]. Folate-producing lactic acid bacilli, Streptococcus (Strep.) thermophilus CRL 808 and Strep. thermophilus CRL 415, have been shown to prevent intestinal inflammation in experimental models and proposed for the treatment of dysbiosis [157]. Probiotics have been proven to prevent EAU in mice, and delivery of folate-producing probiotics offers a safe and tolerable supplement in the treatment of AD [158].

The mechanism of action of folate is distinctly different from other known vitamin-based immunomodulators such as vitamin A/atRA and D, as well as SCFA. While atRA, cholecalciferol (vitamin D3) and SCFA had been found to enhance the peripheral differentiation of naïve T cells into pT_{reg} [172, 116–118], and folate is required during clonal expansion of nT_{reg} [66]. Hence, folate exerts its modulatory effects at two levels in vivo, namely, (1) as a mediator of epigenetic control in thymic nT_{reg} and (2) as an antiapoptotic signal in induced pT_{reg} supporting their survival in the circulation. As adoptive transfer of antigen-experienced T_{reg} prevents development of EAU [88, 90], it would be interesting to see whether folate-treated antigen-experienced (or even naïve) T_{reg} were more effective in control of AD. This could be combined with SCFA to maximize the differentiation of naïve T cells to T_{reg}. Complementary effects of the two metabolites are likely based on their different modes of action.

9. Folate Deficiency and Current Therapy for AD

Folate deficiency has strong implications for overall health and may also complicate the management of AD. Methotrexate (Mtx; amethopterin) is routinely used to manage a range of AD including certain types of uveitis. As indicated above (see Figure 2), the drug’s effectiveness and toxicity vary among individuals and are likely determined by polymorphisms in folate, pyrimidine, and purine metabolic enzymes [159]. The mechanism of action is presumed to be inhibition of T cell proliferation but overall, the efficacy of Mtx in uveitis is limited [160–163]. This may be due to the drug’s competitive antifolate effects. Macrophages are major agents of tissue destruction in AD including uveitis [164, 165] and require high amounts of folate to remain active via high surface expression of the folate receptor FRβ [166, 167]. Mtx is structurally similar to folate with 1000-fold higher affinity for the enzyme dihydrofolate reductase (DHFR) [168, 169] (Figure 3). It thus starves cells with high folate requirement such as activated macrophages, thereby abrogating the cells’ survival and halting disease progression. While this might be of benefit to control tissue-damaging macrophages in noninfectious uveitis [170], there may be a negative side-effect on the T_{reg} function. Thus, the action of Mtx is likely to be rather complex having both antiproliferative and anti-inflammatory roles and targeting activated macrophages as well as T_{reg}. In the event, Mtx seems to be more effective in acute AU (with significant myeloid involvement) than in sight-threatening chronic PU (with Th1 and Th17 T_{eff} cells being the main drivers of disease).

An alternative mechanism for the immunosuppressive effect of Mtx and other immunosuppressants has been proposed: in humans, hypomethylation of the TSDR (T_{reg}-specific demethylated region) is required for the functional stability of peripheraly expanding FoxP3+ pT_{reg} [171] and correlates with the duration of oral immunosuppressive therapy. This indicates that in patients, conventional immunosuppression can induce pT_{reg} leading to remission of the disease (reviewed in [172]). This finding is particularly interesting with regard to folate being a mediator of epigenetic programming (Figure 3) and emphasizes the importance of coordinating appropriate treatment regimens with the dynamics and kinetics of disease progression.

10. Conclusions

Folate as one of the colonic bacterial fermentation products is a powerful micronutrient with a broad spectrum of well-known functions at various levels. Its importance in ocular health is well established [144–146, 173–179], but its immunomodulatory properties represent an emerging concept for functional T_{reg} stabilization. The colon is a significant folate depot [19] that participates in metabolism and contributes to bioavailable folate levels. It is an important immunological organ with “unconventional IP” properties [50] with a core function in oral tolerance [180] and prevention of microbial antigen escape into the general circulation. Pathological structural (“leaky gut”) and/or environment-induced proinflammatory changes (dysbiosis) in the gut therefore jeopardize this role, allowing for the transmigration of commensal antigen into the blood stream. The use of folate- and SCFA-producing microbes has the potential to form the basis for a novel approach to prophylactic control of AD. While emerging data suggests oral probiotics [158, 181] or alternatively FMT [182] might help eliminate dysbiosis, knock-on effects on colonic folate synthesis/bioavailability and its implications for immune cell functioning remain to be explored. As dysbiosis has been found to occur in a range of AD, including uveitis [36, 183, 184], targeted administration of certain beneficial folate-producing bacteria or even direct oral folate treatment in AD merits clinical evaluation as a low-risk effective adjunctive treatment option. A daily oral folate supplementation of 5,000–10,000 μg (i.e., 25–50 times the daily recommendation) is generally well tolerated by healthy, nonpregnant individuals. Neurological side-effects have been reported in cases of pernicious anemia (B12 hypovitaminosis), and interference with intestinal zinc absorption has been demonstrated in animals which is likely irrelevant in humans (reviewed in [185]). Some evidence suggests that long-term folic acid supplementation can promote the progression of preexisting malignant lesions in advanced
age [186]. Importantly, as $T_{reg}$ phenotypes between mice and humans vary to some degree [120, 121], research is needed to clarify those differences and assess whether those AD-attenuating folate effects observed in mice are equally valid in humans. Regardless, folate is an important and undervalued micronutrient with powerful direct and indirect effects in the organism and a potential regulatory role in autoimmunity and chronic inflammation.

**Data Availability**

Original data will be made available upon request.

**Conflicts of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Authors’ Contributions**

CM researched, collated, and summarized available literature, wrote the main body of the paper, created the figures, and edited/formatted the manuscript. JVF and HMW assisted with the conceptualization, writing and revising the text. JK and JVF delivered clinical insight. HMW, JK, and JVF provided expert opinion, edited and critically revised the article.

**Acknowledgments**

The ideas developed in this article were derived from work supported by Fight for Sight, The Eye Charity [CSO project grant award: 3031-3032] awarded to HMW and by the Development Trust of the University of Aberdeen (Saving Sight in Grampian) [grant codes: RG-12663 and RG-14251].

**References**

[1] E. Ben-Chetrit, M. Gattorno, A. Gul et al., “Consensus proposal for taxonomy and definition of the autoimmune inflammatory diseases (AIDs): a Delphi study,” *Annals of the Rheumatic Diseases*, vol. 77, no. 11, pp. 1558–1565, 2018.

[2] W. E. Ruff, T. M. Greiling, and M. A. Kriegel, “Host-microbiota interactions in immune-mediated diseases,” *Nature Reviews Microbiology*, vol. 18, no. 9, pp. 521–538, 2020.

[3] S. N. Choileáin, M. Kleineveldt, K. Raddassi, D. A. Hafler, W. E. Ruff, and E. E. Longbrake, “CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome,” *Journal of Translational Autoimmunity*, vol. 3, p. 100032, 2020.

[4] S. Dedrick, B. Sundaresh, Q. Huang et al., “The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis,” *Frontiers in Endocrinology*, vol. 11, p. 78, 2020.

[5] J. Manasson, R. B. Blank, and J. U. Scher, “The microbiome in rheumatology: where are we and where should we go?,” *Annals of the Rheumatic Diseases*, vol. 79, no. 6, pp. 727–733, 2020.

[6] M. Vural, B. Gilbert, I. Üstün, S. Caglar, and A. Finckh, “Mini-review: human microbiome and rheumatic diseases,” *Frontiers in Cellular and Infection Microbiology*, vol. 10, 2020.

[7] J. V. Forrester, L. Kuffova, and A. D. Dick, “Autoimmunity, autoinflammation, and infection in uveitis,” *American Journal of Ophthalmology*, vol. 189, pp. 77–85, 2018.

[8] M. P. Schön, “Adaptive and innate immunity in psoriasis and other inflammatory disorders,” *Frontiers in Immunology*, vol. 10, 2019.

[9] M. Romano, G. Panelli, C. J. Albany, G. Giganti, and G. Lombardi, “Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity,” *Frontiers in Immunology*, vol. 10, p. 43, 2019.

[10] M. Li, X. Zhou, L. Zhou, Z. Yu, L. Fu, and P. Yang, “Meta-analysis of changes in the number and proportion of regulatory T cells in patients with ankylosing spondylitis,” *BioMed Research International*, vol. 2020, 15 pages, 2020.

[11] A. Ratsika, M. C. Codagnone, S. O’Mahony, C. Stanton, and J. F. Cryan, “Priming for life: early life nutrition and the microbiota-gut-brain axis,” *Nutrients*, vol. 13, no. 2, p. 423, 2021.

[12] U. Simeoni, J.-B. Armengaud, B. Siddeek, and J.-F. Tolsa, “Peroxisome proliferator-activated receptor gamma in health and disease,” *Physiological Reviews*, vol. 90, no. 3, pp. 859–904, 2010.

[13] B. W. Chow and C. Gu, “Gradual suppression of transcytosis governs functional blood-retinal barrier formation,” *Neuron*, vol. 93, no. 6, pp. 1325–1333.e3, 2017.

[14] S. Ogura, K. Kurata, Y. Hattori et al., “Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown,” *JCI Insight*, vol. 2, no. 3, p. e90905, 2017.

[15] I. Sekirov, S. L. Russell, L. C. M. Antunes, and B. B. Finlay, “Gut microbiota in health and disease,” *Physiological Reviews*, vol. 90, no. 3, pp. 859–904, 2010.

[16] J. K. Griffiths, *144 - Vitamin Deficiencies, in Hunter’s Tropical Medicine and Emerging Infectious Diseases*, E. T. Ryan, Ed., Content Repository Only, London, Tenth edition, 2020.

[17] WHO, *Vitamin and mineral requirements in human nutrition*, Second edition, , 2004https://pubhtml5.com/ulqt/prcv/prcv/basic.

[18] J. A. Greenberg, S. J. Bell, Y. Guan, and Y.-H. Yu, “Folic acid supplementation and pregnancy: more than just neural tube defect prevention,” *Reviews in Obstetrics and Gynecology*, vol. 4, no. 2, pp. 52–59, 2011.

[19] D. E. Kok, W. T. Steegenga, and J. A. McKay, “Folates and epigenetics: why we should not forget bacterial biosynthesis,” *Epigenomics*, vol. 10, no. 9, pp. 1147–1150, 2018.

[20] R. L. Blakley, “Nomenclature and symbols for folic acid and related compounds. Recommendations 1986,” *European Journal of Biochemistry*, vol. 168, no. 2, pp. 251–253, 1987.

[21] V. E. Ohrvik and C. M. Witthoft, “Human Folate Bioavailability,” *Nutrients*, vol. 3, no. 4, pp. 475–490, 2011.

[22] I. H. Rosenberg and J. W. Miller, “Nutritional factors in physiological and cognitive functions of elderly people,” *American Journal of Clinical Nutrition*, vol. 55, no. 6, pp. 1237S–1245S, 1992.

[23] J. Selhub, L. C. Bagley, J. Miller, and I. H. Rosenberg, “B vitamins, homocysteine, and neurocognitive function in the elderly,” *The American Journal of Clinical Nutrition*, vol. 71, no. 2, pp. 614S–620S, 2000.
L. G. Albenberg and G. D. Wu, "Nutritional challenges for older adults in Europe: current status and future directions," *The Proceedings of the Nutrition Society*, vol. 78, no. 2, pp. 221–233, 2019.

R. Horai and R. R. Caspi, "Microbiome and autoimmune uveitis," *Frontiers in Immunology*, vol. 10, 2019.

R. Horai, C. R. Zárate-Bladés, P. Dillenburg-Pilla et al., "Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site," *Immunity*, vol. 43, no. 2, pp. 343–353, 2015.

G. L. V. de Oliveira, A. Z. Leite, B. S. Higuchi, M. I. Gonzaga, and V. S. Mariano, "Intestinal dysbiosis and probiotic applications in autoimmune diseases," *Immunology*, vol. 152, no. 1, pp. 1–12, 2017.

Q. Mu, J. Kirby, C. M. Reilly, and X. M. Luo, "Leaky gut as a danger signal for autoimmune diseases," *Frontiers in Immunology*, vol. 8, 2017.

J.-F. Bach, "The hygiene hypothesis in autoimmunity: the role of pathogens and commensals," *Nature Reviews Immunology*, vol. 18, no. 2, pp. 105–120, 2018.

M. Levy, A. A. Kolodziejczyk, C. A. Thaiss, and E. Elinav, "Dysbiosis and the immune system," *Nature Reviews Immunology*, vol. 17, no. 4, pp. 219–232, 2017.

L. W. Peterson and D. Artis, "Intestinal epithelial cells: regulators of barrier function and immune homeostasis," *Nature Reviews Immunology*, vol. 14, no. 3, pp. 141–153, 2014.

S. R. Gill, M. Pop, R. T. Deboy et al., "Metagenomic analysis of the human distal gut microbiome," *Science*, vol. 312, no. 5778, pp. 1355–1359, 2006.

M. Rajilić-Stojanović and W. M. de Vos, "The first 1000 cultured species of the human gastrointestinal microbiota," *FEMS Microbiology Reviews*, vol. 38, no. 5, pp. 996–1047, 2014.

J. Qin, M. H. I. T. Consortium, R. Li et al., "A human gut microbial gene catalogue established by metagenomic sequencing," *Nature*, vol. 464, no. 7285, pp. 59–65, 2010.

L. G. Albenberg and G. D. Wu, "Diet and the intestinal microbiome: associations, functions, and implications for health and disease," *Gastroenterology*, vol. 146, no. 6, pp. 1564–1572, 2014.

S. K. Chakravartthy, R. Jayasudha, G. S. Prashanthi et al., "Dysbiosis in the gut bacterial microbiome of patients with uveitis, an inflammatory disease of the eye," *Indian Journal of Microbiology*, vol. 58, no. 4, pp. 457–469, 2018.

A.-I. Suceveanu, A. Dumitrău, M. Musat et al., "Is a fecal microbiota transplant useful for treating inflammatory bowel disease?," in *Human Microbiome [working title]*, IntechOpen, 2019.

Y. Bordon, "A microbial trigger for colitis," *Nature Reviews Immunology*, vol. 19, no. 6, pp. 350–351, 2019.

S. Shivaji, "Connect between gut microbiome and diseases of the human eye," *Journal of Biosciences*, vol. 44, no. 5, 2019.

W.-J. H. Wu, D. F. Zegarra-Ruiz, and G. E. Diehl, "Intestinal microbes in autoimmune and inflammatory disease," *Frontiers in Immunology*, vol. 11, 2020.

P. Hofley, J. Roarty, G. McGinnity et al., "Asymptomatic uveitis in children with chronic inflammatory bowel diseases," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 17, no. 4, pp. 397–400, 1993.

P. J. Rychwalski, O. A. Cruz, G. Alanis-Lambretón, T. M. Foy, and R. E. Kane, "Asymptomatic uveitis in young people with inflammatory bowel disease," *Journal of AAPOS*, vol. 1, no. 2, pp. 111–114, 1997.

S. Yilmaz, E. Aydemir, A. Maden, and B. Unsal, "The prevalence of ocular involvement in patients with inflammatory bowel disease," *International Journal of Colorectal Disease*, vol. 22, no. 9, pp. 1027–1030, 2007.

F. C. Edwards and S. C. Trueove, "The course and prognosis of ulcerative COLITIS. III. COMPLICATIONS," *Gut*, vol. 5, pp. 1–22, 1964.

C.-N. Zhao, Z. Xu, G. C. Wu et al., "Emerging role of air pollution in autoimmune diseases," *Autoimmunity Reviews*, vol. 18, no. 6, pp. 607–614, 2019.

A. Vojdani, "A potential link between environmental triggers and autoimmunity," *Autoimmune Diseases*, vol. 2014, Article ID 437231, 18 pages, 2014.

J. Spadoni, G. Fornasa, and M. Riesgo, "Organ-specific protection mediated by cooperation between vascular and epithelial barriers," *Nature Reviews Immunology*, vol. 17, no. 12, pp. 761–773, 2017.

B. Chassaing, M. Kumar, M. T. Baker, V. Singh, and M. Vijay-Kumar, "Mammalian gut immunity," *Biomedical Journal*, vol. 37, no. 5, pp. 246–258, 2014.

S. P. Spencer, G. K. Fragiadakis, and J. L. Sonnenberg, "Pursuing human-relevant gut Microbiota-immune interactions," *Immunity*, vol. 51, no. 2, pp. 225–239, 2019.

R. Shechter, A. London, and M. Schwartz, "Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates," *Nature Reviews Immunology*, vol. 13, no. 3, pp. 206–218, 2013.

C. Möller, J. Heissigerova, H. M. Wilson, L. Kuffova, and J. V. Forrester, "Immune privilege: the microbiome and uveitis," *Frontiers in Immunology*, vol. 11, pp. 608377–608377, 2021.

B. Lee, K. M. Moon, and C. Y. Kim, "Tight junction in the intestinal epithelium: its association with diseases and regulation by phytochemicals," *Journal of Immunology Research*, vol. 2018, Article ID 2645465, 11 pages, 2018.

R. Daneman and M. Riesgo, "The gut immune barrier and the blood-brain barrier: are they so different?," *Immunity*, vol. 31, no. 5, pp. 722–735, 2009.

R. E. Ley, D. A. Peterson, and J. J. Gordon, "Ecological and evolutionary forces shaping microbial diversity in the human intestine," *Cell*, vol. 124, no. 4, pp. 837–848, 2006.

I. Spadoni, E. Zagato, A. Bertocchi et al., "A gut-vascular barrier controls the systemic dissemination of bacteria," *Science*, vol. 350, no. 6262, pp. 830–834, 2015.

T. G. Bush, T. C. Savidge, T. C. Freeman et al., "Fulminating jejuno-ileitis following activation of enteric glia in adult transgenic mice," *Cell*, vol. 93, no. 2, pp. 189–201, 1998.

A. Cornet, T. C. Savidge, J. Cabarrocas et al., "Enterocolitis induced by autoimmunity targeting of enteric glial cells: a possible mechanism in Crohn's disease?," *Proceedings of the National Academy of Sciences*, vol. 98, no. 23, pp. 13306–13311, 2001.

D. Erny, A. L. H. de Angelis, A. D. Jaitin et al., "Microbiota-dependent activation of an autoreactive T cell," *Nature Immunology*, vol. 10, no. 2, pp. 189–201, 2009.

P. S. Kabouridis, R. Lasrado, S. McCallum et al., "Microbiota controls the homeostasis of glial cells in the gut lamina propria," *Neuron*, vol. 85, no. 2, pp. 289–295, 2015.
S. Xiao, H. Jin, T. Korn et al., G. den Besten, K. van Eunen, A. K. Groen, K. Venema, D. J. Reijnoud, and B. M. Bakker, "The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism," Journal of Lipid Research, vol. 54, no. 9, pp. 2325–2340, 2013.

C. M. Trujillo-Vargas, L. Schaefer, J. Alam, S. Pflugfelder, R. A. Britton, and C. S. de Paiva, "The gut-eye-lacrimal gland-microbiome axis in Sjogren syndrome," The Ocular Surface, vol. 18, no. 2, pp. 335–344, 2020.

N. Arpaia, C. Campbell, X. Fan et al., "Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation," Nature, vol. 504, no. 7480, pp. 451–455, 2013.

E. Mariño, J. L. Richards, K. H. McLeod et al., "Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes," Nature Immunology, vol. 18, no. 5, pp. 552–562, 2017.

J. Gong, W. Qiu, Q. Zeng et al., "Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: a Chinese pilot study," Multiple Sclerosis Journal, vol. 25, no. 9, pp. 1316–1325, 2019.

Q. Zeng, Junli Gong, X. Liu et al., "Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis," Neurochemistry International, vol. 129, article 104468, 2019.

C. C. Blad, C. Tang, and S. Offermanns, "G protein-coupled receptors for energy metabolites as new therapeutic targets," Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 603–619, 2012.

N. Singh, A. Gurav, S. Sivaprakasam et al., "Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis," Immunity, vol. 40, no. 1, pp. 128–139, 2014.

M. A. Engevik, C. N. Morra, D. Röth et al., "Microbial metabolic capacity for intestinal folate production and modulation of host folate receptors," Frontiers in Microbiology, vol. 10, pp. 2305–2305, 2019.

A. M. Morton, E. Sefik, R. Upadhyay, R. Weissleder, C. Benoist, and D. Mathis, "Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut," Proceedings of the National Academy of Sciences, vol. 111, no. 18, pp. 6696–6701, 2014.

Y. K. Nakamura, C. Janowitz, C. Metea et al., "Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine," Scientific Reports, vol. 7, no. 1, p. 11745, 2017.

S. Q. Liu, P. K. Alkema, C. Tiechê et al., "Negative regulation of monocyte adhesion to arterial elastic laminae by signal regulatory protein α and Src homology 2 domain-containing protein-tyrosine phosphatase-1," The Journal of Biological Chemistry, vol. 280, no. 47, pp. 39294–39301, 2005.

Y. Hara, R. R. Caspi, B. Wiggert, C. C. Chan, G. A. Wilbanks, and J. W. Streilein, "Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein," The Journal of Immunology, vol. 148, no. 6, pp. 1685–1692, 1992.

T. Lambe, J. C. H. Leung, H. Ferry et al., "Limited peripheral T cell anergy predisposes to retinal autoimmunity," The Journal of Immunology, vol. 178, no. 7, pp. 4276–4283, 2007.

Y.-H. Liu, C. Mölzer, K. Makinen et al., "Treatment with FoxP3+ antigen-experienced T regulatory cells arrests progressive retinal damage in a spontaneous model of uveitis," Frontiers in Immunology, vol. 11, p. 2071, 2020.
[91] R. A. Prendergast, C. E. Iliff, N. M. Coskuncan et al., “T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis,” Investigative Ophthalmology & Visual Science, vol. 39, no. 5, pp. 754–762, 1998.

[92] R. R. Caspi, R. Horai, C. Zárate-Blades et al., “Activation of autoreactive T cells by endogenous commensal microflora provokes spontaneous autoimmunity in the immunologically privileged eye,” Investigative Ophthalmology & Visual Science, vol. 55, no. 13, pp. 4600, 2014.

[93] M. M. M. Kaisar, L. R. Pelgrom, A. J. van der Ham, M. Yazdanbakhsh, and B. Everts, “Butyrate Conditions Human Dendritic Cells to Prime Type 1 Regulatory T Cells via both Histone Deacetylase Inhibition and G Protein-Coupled Receptor 109A Signaling,” Frontiers in Immunology, vol. 8, p. 1429, 2017.

[94] A. Luo, S. T. Leach, R. Barres, L. B. Hesson, M. C. Grimm, and D. Simar, “The microbiota and epigenetic regulation of T Helper 17/regulatory T cells: in search of a balanced immune system,” Frontiers in Immunology, vol. 8, p. 417, 2017.

[95] S. Fukuda, H. Toh, K. Hase et al., “Bifidobacteria can protect from enteropathogenic infection through production of acetate,” Nature, vol. 469, no. 7331, pp. 543–547, 2011.

[96] L. Macia, J. Tan, A. T. Vieira et al., “Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome,” Nature Communications, vol. 6, no. 1, p. 6734, 2015.

[97] E. L. Johnson, S. L. Heaver, W. A. Walters, and R. E. Ley, “Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes,” Journal of Molecular Medicine (Berlin, Germany), vol. 95, no. 1, pp. 1–8, 2017.

[98] E. E. Putnam and A. L. Goodman, “B vitamin acquisition by gut commensal bacteria,” PLoS Pathogens, vol. 16, no. 1, p. e1008208, 2020.

[99] T. Ichihashi, Y. Takagishi, K. Uchida, and H. Yamada, “Colon absorption of Menaquinone-4 and Menaquinone-9 in rats,” The Journal of Nutrition, vol. 122, no. 3, pp. 506–512, 1992.

[100] H. M. Said and Z. M. Mohammed, “Intestinal absorption of water-soluble vitamins: an update,” Current Opinion in Gastroenterology, vol. 22, no. 2, pp. 140–146, 2006.

[101] S. Aufreiter, J. F. Gregory III, C. M. Pfeiffer et al., “Folate is absorbed across the colon of adults: evidence from cecal infusion of 13C-labeled [6S]-5-formyltetrahydrofolic acid,” The American Journal of Clinical Nutrition, vol. 90, no. 1, pp. 116–123, 2009.

[102] A. Lakoﬀ, Z. Fazili, S. Aufreiter et al., “Folate is absorbed across the human colon: evidence by using enteric-coated caplets containing 13C-labeled [6S]-5-formyltetrahydrofolate,” The American Journal of Clinical Nutrition, vol. 100, no. 5, pp. 1278–1286, 2014.

[103] C. Awuchi, I. Victory, and A. Ikechukwu, “Nutritional diseases and nutrient toxicities: a systematic review of the diets and nutrition for prevention and treatment,” International Journal of Advanced Academic Research, vol. 6, no. 1, pp. 1–46, 2020.

[104] P. Chappert and R. H. Schwartz, “Induction of T cell anergy: integration of environmental cues and infectious tolerance,” Current Opinion in Immunology, vol. 22, no. 5, pp. 552–559, 2010.

[105] I. A. Kalekar and D. L. Mueller, “Relationship between CD4 regulatory T cells and Anergy in vivo,” The Journal of Immunology, vol. 198, no. 7, pp. 2527–2533, 2017.

[106] D. L. Mueller, “Mechanisms maintaining peripheral tolerance,” Nature Immunology, vol. 11, no. 1, pp. 21–27, 2010.

[107] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008.

[108] R. J. Martinez, N. Zhang, S. R. Thomas et al., “Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hianergic state in the presence of Foxp3+regulatory T cells,” The Journal of Immunology, vol. 188, no. 1, pp. 170–181, 2012.

[109] M. S. Morales and D. Mueller, “Anergy into T regulatory cells: an integration of metabolic cues and epigenetic changes at the Foxp3 conserved non-coding sequence 2,” F1000Research, vol. 7, 2018.

[110] L. A. Kalekar, S. E. Schmied, S. L. Nandiwada et al., “CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors,” Nature Immunology, vol. 17, no. 3, pp. 304–314, 2016.

[111] Y. Zheng, S. Josefowicz, A. Chaudhry, X. P. Peng, K. Forbush, and A. Y. Rudensky, “Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate,” Nature, vol. 463, no. 7328, pp. 808–812, 2010.

[112] X. Li, Y. Liang, M. LeBlanc, C. Benner, and Y. Zheng, “Function of a Foxp3_cis_element in protecting regulatory T cell identity,” Cell, vol. 158, no. 4, pp. 734–748, 2014.

[113] Z. Zhang and X. Zhou, “Foxp3 Instability Helps Tregs Distinguish Self and Non-self,” Frontiers in Immunology, vol. 10, p. 2226, 2019.

[114] C. Schmidl, M. Klug, T. J. Boeld et al., “Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity,” Genome Research, vol. 19, no. 7, pp. 1165–1174, 2009.

[115] Y. Yoshioka, T. Kozaki, K. Ishii, A. Toyoda, M. Hattori, and T. Yoshida, “Comprehensive analysis of epigenetically regulated genes in anergic T cells,” Cellular Immunology, vol. 311, pp. 71–79, 2017.

[116] J. L. Coombes, K. R. R. Siddiqui, C. V. Arancibia-Cárcamo et al., “A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β- and retinoic acid–dependent mechanism,” Journal of Experimental Medicine, vol. 204, no. 8, pp. 1757–1764, 2007.

[117] C.-M. Sun, J. A. Hall, R. B. Blank et al., “Small intestine lamina propria dendritic cells promote de novo generation of Foxp3+ reg cells via retinoic acid,” The Journal of Experimental Medicine, vol. 204, no. 8, pp. 1775–1785, 2007.

[118] M. J. Benson, K. Pino-Lagos, M. Roseblatt, and R. J. Noelle, “All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation,” The Journal of Experimental Medicine, vol. 204, no. 8, pp. 1765–1774, 2007.

[119] S. Piantoni, L. Andreoli, M. Scarsi et al., “Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D,” Lupus, vol. 24, no. 4-5, pp. 490–498, 2015.

[120] M. E. Morgan, J. H. M. van Bilsen, A. M. Bakker et al., “Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans,” Human Immunology, vol. 66, no. 1, pp. 13–20, 2005.
Microbiota determines susceptibility to experimental autoimmune uveitis in mice, *Mediators of Inflammation*, vol. 2018, Article ID 9129163, 13 pages, 2018.

Y. Wei, S. Chen, D. Sun et al., "miR-223-3p promotes auto-reactive T/H17 cell responses in experimental autoimmune uveitis (EAU) by inhibiting transcription factor FOXP3 expression," *The FASEB Journal*, vol. 33, no. 12, pp. 13951–13965, 2019.

F. H. Verhagen, C. P. J. Bekker, M. Rossato et al., "A disease-associated MicroRNA cluster links inflammatory pathways and an altered composition of leukocyte subsets to noninfectious uveitis," *Investigative Ophthalmology & Visual Science*, vol. 59, no. 2, pp. 878–888, 2018.

H. Zhou, J. Xiao, N. Wu et al., "MicroRNA-223 regulates the differentiation and function of intestinal dendritic cells and macrophages by targeting C/EBPβ," *Cell Reports*, vol. 13, no. 6, pp. 1149–1160, 2015.

V. Neudecker, M. Haneklaus, O. Jensen et al., "Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome," *Journal of Experimental Medicine*, vol. 214, no. 6, pp. 1737–1752, 2017.

H. Wang, K. Chao, S. C. Ng et al., "Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease," *Genome Biology*, vol. 17, no. 1, p. 58, 2016.

M. Messedi, M. Frigui, K. Chaabouni et al., "Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and variations of homocysteine concentrations in patients with Behcet's disease," *Gene*, vol. 527, no. 1, pp. 306–310, 2013.

A. E. Elbay, A. Topalkara, A. Elbay, H. Erdogan, A. Vural, and A. B. Çetin, "Evaluation of serum homocysteine and leptin levels in patients with uveitis," *Turkish Journal of Ophthalmology*, vol. 45, no. 4, pp. 146–151, 2015.

O. Sijilmassi, "Folic acid deficiency and vision: a review," *Graefe's Archive for Clinical and Experimental Ophthalmology*, vol. 257, no. 8, pp. 1573–1580, 2019.

T. Marrs and J. Walter, "Pros and cons: is faecal Microbiota transplantation a safe and efficient treatment option for gut dysbiosis?" *Allergy*, 2021.

Z. Ye, C. Wu, N. Zhang et al., "Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease," *Gut Microbes*, vol. 11, no. 3, pp. 539–555, 2020.

E. C. Rosser, C. J. M. Piper, D. E. Matei et al., "Microbiota-derived metabolites suppress arthritis by amplifying arylhydrocarbon receptor activation in regulatory B cells," *Cell Metabolism*, vol. 31, no. 4, pp. 837–851.e10, 2020.

N. Chen, J. Wu, J. Wang et al., "Short chain fatty acids inhibit endotoxin-induced uveitis and inflammatory responses of retinal astrocytes," *Experimental Eye Research*, vol. 206, article 108520, 2021.

A. Duscha, B. Gisevius, S. Hirschberg et al., "Propionic acid shapes the multiple sclerosis disease course by an
immunomodulatory mechanism,” Cell, vol. 180, no. 6, pp. 1067–1080.e16, 2020.

[152] P. Elo, X. G. Li, H. Liljenbäck et al., “Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis,” Journal of Neuroinflammation, vol. 18, no. 1, p. 30, 2021.

[153] Y. Lu, K. N. Wollak, V. A. Cross et al., “Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis,” Clinical Immunology, vol. 150, no. 1, pp. 64–77, 2014.

[154] E. Nogueira, A. C. Gomes, A. Preto, and A. Cavaco-Paulo, “Folate-targeted nanoparticles for rheumatoid arthritis therapy,” Nanomedicine: Nanotechnology, Biology, vol. 12, no. 4, pp. 1113–1126, 2016.

[155] E. Evans, L. Piccio, and A. H. Cross, “Use of vitamins and dietary supplements by patients with multiple sclerosis: a review,” JAMA Neurology, vol. 75, no. 8, pp. 1013–1021, 2018.

[156] M. E. Sanders, D. J. Merenstein, G. Reid, G. R. Gibson, and R. A. Rastall, "Prebiotics and prebiotics in intestinal health and disease: from biology to the clinic," Nature Reviews Gastroenterology, vol. 16, no. 10, pp. 605–616, 2019.

[157] A. de Moreno de LeBlanc, R. Levit, G. S. de Giori, and J. G. LeBlanc, “Vitamin producing lactic acid bacteria as complementary treatments for intestinal inflammation,” Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, vol. 17, no. 1, pp. 50–56, 2018.

[158] O. Dusek, A. Fajstova, A. Klimova et al., “Severity of experimental autoimmune uveitis is reduced by pretreatment with live probiotic Escherichia coli nissle 1917,” Cell, vol. 10, no. 1, p. 23, 2021.

[159] E. Campalani, M. Arenas, A. M. Marinaki, C. M. Lewis, J. N. W. N. Barker, and C. H. Smith, “Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis,” Journal of Investigative Dermatology, vol. 127, no. 8, pp. 1860–1867, 2007.

[160] S. Gangaputra, C. W. Newcomb, T. L. Liesegang et al., “Methotrexate for ocular inflammatory diseases,” Ophthalmology, vol. 116, no. 11, pp. 2188–2198.e1, 2009, e1.

[161] C. S. Ma and T. G. Phan, “Here, there and everywhere: T follicular helper cells on the move,” Immunology, vol. 152, no. 3, pp. 382–387, 2017.

[162] S. Muñoz-Fernández and E. Martín-Mola, “Uveitis,” Best Practice & Research. Clinical Rheumatology, vol. 20, no. 3, pp. 487–505, 2006.

[163] C. M. Samson, N. Waheed, S. Baltatzis, and C. S. Foster, “Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients,” Ophthalmology, vol. 108, no. 6, pp. 1134–1139, 2001.

[164] H. R. Chinnery, P. G. McMenamin, and S. J. Dando, “Macrophage physiology in the eye,” Pflügers Archiv - European Journal of Physiology, vol. 469, no. 3-4, pp. 501–515, 2017.

[165] Multicenter Uveitis Steroid Treatment Trial Research Group, J. H. Kempen, M. M. Altaweel, J. T. Holbrook, D. A. Jabs, and E. A. Sugar, “The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics,” American Journal of Ophthalmology, vol. 149, no. 4, pp. 550–561.e10, 2010.

[166] N. Nakashima-Matsushita, T. Homma, S. Yu et al., “Selective expression of folate receptor ? and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis,” Arthritis & Rheumatology, vol. 42, no. 8, pp. 1609–1616, 1999.

[167] W. Xia, A. R. Hilgenbrink, E. L. Matteson, M. B. Lockwood, J. X. Cheng, and P. S. Low, “A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages,” Blood, vol. 113, no. 2, pp. 438–446, 2009.

[168] E. J. Pastore, R. L. Kisluk, L. T. Plante, J. M. Wright, and N. O. Kaplan, “Conformational changes induced in dihydrofolate reductase by folates, pyridine nucleotide coenzymes, and methotrexate,” Proceedings of the National Academy of Sciences, vol. 71, no. 10, pp. 3849–3853, 1974.

[169] J. W. Williams, J. F. Morrison, and R. G. Duggleby, “Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase,” Biochemistry, vol. 18, no. 12, pp. 2567–2573, 1979.

[170] A. Gangaplera, C. Massilamany, D. Steffen, and J. Reddy, “Mimicry epitope from_Ehrlichia canis_ for interphotoreceptor retinoid-binding protein 201 -216 prevents autoimmune uveoretinitis by acting as altered peptide ligand,” Journal of Neuroimmunology, vol. 263, no. 1-2, pp. 98–107, 2013.

[171] L. Schreiber, B. Pietzsch, S. Floess et al., “The Treg-specific demethylated region stabilizes Foxp3 expression independently of NF-xB signaling,” PLoS One, vol. 9, no. 2, article e88318, 2014.

[172] G. Wildner and M. Diedrichs-Möhring, “Resolution of uveitis,” Seminars in Immunopathology, vol. 41, no. 6, pp. 727–736, 2019.

[173] S. Bleich, J. Kornhuber, and A. G. Junemann, “Homocysteine in primary and secondary open-angle glaucoma,” Journal of Glaucoma, vol. 12, no. 6, pp. 498–499, 2003, author reply 499.

[174] P. de Silva, G. Jayamanne, and R. Bolton, “Folic acid deficiency optic neuropathy: a case report,” Journal of Medical Case Reports, vol. 2, no. 1, p. 299, 2008.

[175] P. Huang, F. Wang, B. Kumar Sah et al., “Homocysteine and the risk of age-related macular degeneration: a systematic review and meta-analysis,” Scientific Reports, vol. 5, no. 1, article 10585, 2015.

[176] D. L. Knox, M. F. Chen, T. R. Guilarte, C. V. Dang, and J. Burnette, “Nutritional amblyopia. Folic acid, vitamin B-12, and other vitamins,” Retina, vol. 2, no. 4, pp. 288–293, 1982.

[177] K. J. Moore, S. L. Carmichael, N. E. Forestieri et al., “Maternal diet as a risk factor for primary congenital glaucoma and defects of the anterior segment of the eye in the National Birth Defects Prevention Study,” Birth Defects Research, vol. 112, no. 6, pp. 503–514, 2020.

[178] S. K. Sen, P. Pukazhvanthen, and R. Abraham, “Plasma homocysteine, folate and vitamin B(12) levels in senile cata- ract,” Indian Journal of Clinical Biochemistry, vol. 23, no. 3, pp. 255–257, 2008.

[179] C. Xu, Y. Wu, G. Liu, X. Liu, F. Wang, and J. Yu, “Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis,” Diagnostic Pathology, vol. 9, no. 1, p. 167, 2014.

[180] A. Goubier, B. Dubois, H. Gheit et al., “Plasmacytoid dendritic cells mediate oral tolerance,” Immunity, vol. 29, no. 3, pp. 464–475, 2008.
[181] J. Kim, S. Choi, Y. Kim et al., "Clinical Effect of IRT-5 probiotics on immune modulation of autoimmunity or alloimmunity in the eye," *Nutrients*, vol. 9, no. 11, p. 1166, 2017.

[182] R. Y. Choi, M. Asquith, and J. T. Rosenbaum, "Fecal transplants in spondyloarthritis and uveitis: ready for a clinical trial?," *Current Opinion in Rheumatology*, vol. 30, no. 4, pp. 303–309, 2018.

[183] X. Huang, Z. Ye, Q. Cao et al., "Gut Microbiota composition and fecal metabolic phenotype in patients with acute anterior uveitis," *Investigative Ophthalmology & Visual Science*, vol. 59, no. 3, pp. 1523–1531, 2018.

[184] R. Jayasudha, S. Kalyana Chakravarthy, G. Sai Prashanthi, S. Sharma, M. Tyagi, and S. Shivaji, "Implicating dysbiosis of the gut fungal microbiome in uveitis, an inflammatory disease of the eye," *Investigative Ophthalmology & Visual Science*, vol. 60, no. 5, pp. 1384–1393, 2019.

[185] C. E. Butterworth Jr. and T. Tamura, "Folic acid safety and toxicity: a brief review," *The American Journal of Clinical Nutrition*, vol. 50, no. 2, pp. 353–358, 1989.

[186] T. N. Wien, E. Pike, T. Wiśniewski, A. Staff, S. Smeland, and M. Klemp, "Cancer risk with folic acid supplements: a systematic review and meta-analysis," *BMJ Open*, vol. 2, no. 1, article e000653, 2012.